Phase II pilot study of pembrolizumab (PEM) and neoadjuvant radiation therapy (nRT) in high-risk soft tissue sarcomas (STS).
Shannon Maxwell, Rylee Johnson, Stephanie K. Schaub, Michael J. Wagner et al.
Journal
Journal of Clinical Oncology
Topics
Sarcoma Diagnosis and Treatment
article
Phase II pilot study of pembrolizumab (PEM) and neoadjuvant radiation therapy (nRT) in high-risk soft tissue sarcomas (STS).
Shannon Maxwell, Rylee Johnson, Stephanie K. Schaub, Michael J. Wagner, Seth M. Pollack, Matthew J. Thompson, Jesse Roberts, Ruohui Chen, Elizabeth T. Loggers, Roxanne Moore, Lee Cranmer, Cecilia Yeung, Niall Morin, Jeremy Sharib, Ralph Graeme Black, Anshu Bandhlish, Edward Y. Kim, Eleanor Y. Chen, David Siu, Harveshp Mogal
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 44(16_suppl)
Institutions
Northwestern University (US), City Of Hope National Medical Center (US), University of Washington (US), University of Washington Medical Center (US), Fred Hutch Cancer Center (US), Dana-Farber Cancer Institute (US)